Microbix Biosystems Inc.
MBX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.54% | -29.91% | -41.09% | -32.13% | -11.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.54% | -29.91% | -41.09% | -32.13% | -11.19% |
| Cost of Revenue | -16.28% | 8.91% | -22.45% | -11.98% | -23.90% |
| Gross Profit | -46.97% | -53.62% | -56.45% | -49.08% | 0.19% |
| SG&A Expenses | 0.05% | 2.80% | 6.54% | 3.49% | 10.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.75% | 4.48% | -8.28% | -3.70% | -8.71% |
| Operating Income | -538.29% | -188.50% | -290.29% | -1,128.91% | -39.18% |
| Income Before Tax | -7,242.36% | -236.75% | -357.50% | -758.51% | -94.86% |
| Income Tax Expenses | -- | -- | -136.68% | -- | -- |
| Earnings from Continuing Operations | -7,242.36% | -236.75% | -433.02% | -758.51% | -94.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7,242.36% | -236.75% | -433.02% | -758.51% | -94.86% |
| EBIT | -538.29% | -188.50% | -290.29% | -1,128.91% | -39.18% |
| EBITDA | -213.65% | -139.37% | -225.63% | -257.82% | -21.07% |
| EPS Basic | -7,500.00% | -233.33% | -443.48% | -746.15% | -95.00% |
| Normalized Basic EPS | -4,700.00% | -235.71% | -304.00% | -1,866.67% | -92.31% |
| EPS Diluted | -7,500.00% | -239.53% | -452.17% | -769.23% | -95.00% |
| Normalized Diluted EPS | -4,700.00% | -235.71% | -304.00% | -1,866.67% | -92.31% |
| Average Basic Shares Outstanding | -0.84% | 3.07% | -2.92% | 2.73% | 1.80% |
| Average Diluted Shares Outstanding | -1.35% | 2.59% | -3.43% | 2.17% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |